MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Medigus Ltd. Total Assets 2011-2025 | MDGS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Medigus Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.5 M | 63.9 M | 97.7 M | 59.7 M | - | 13.3 M | 11.2 M | 7.21 M | 4.72 M | 47.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.7 M | 4.72 M | 38.1 M |
Quarterly Total Assets Medigus Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 59.7 M | - | 63.6 M | - | 32.3 M | - | 17.9 M | - | 13.3 M | - | 9.66 M | - | 11.2 M | - | 4.8 M | - | 7.21 M | - | - | - | 4.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 63.6 M | 4.72 M | 22.5 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 96.13 | 0.04 % | $ 141 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.6 | - | $ 125 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 301.75 | 0.24 % | $ 8.51 B | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 48.12 | 0.21 % | $ 7.17 K | USA |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 124.81 | 0.22 % | $ 217 B | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 2.97 | 4.58 % | $ 111 M |  France |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
InMode Ltd.
INMD
|
786 M | $ 14.47 | 0.7 % | $ 1.15 B |  Israel |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.14 | 3.64 % | $ 18.4 M | USA |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 97.06 | 0.48 % | $ 1.23 B | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
LivaNova PLC
LIVN
|
2.51 B | $ 63.08 | -0.27 % | $ 3.42 B |  Britain |
 |
LENSAR
LNSR
|
66.3 M | $ 12.01 | -0.08 % | $ 138 M | USA |
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 9.54 | - | $ 685 M | Israel |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 157.84 | 0.69 % | $ 11.8 B | USA |
 |
NanoVibronix
NAOV
|
3.63 M | - | - | $ 1.08 M | USA |
 |
Accuray Incorporated
ARAY
|
470 M | $ 0.86 | 0.43 % | $ 88.4 M | USA |
 |
Myomo
MYO
|
10.2 M | $ 1.02 | 12.09 % | $ 7.19 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 14.49 | 0.84 % | $ 392 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 14.53 | 0.07 % | $ 95.2 M | USA |
 |
AxoGen
AXGN
|
204 M | $ 32.64 | -0.61 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 40.17 | 1.34 % | $ 1.24 B | USA |
 |
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
473 M | $ 17.41 | 0.75 % | $ 402 M | USA |
 |
Globus Medical
GMED
|
5.25 B | $ 88.43 | -0.38 % | $ 12 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 12.66 | 0.56 % | $ 975 M | USA |